Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / ARDS - Aridis Pharma's AR-105 flunks mid-stage study; shares down 27% premarket


ARDS - Aridis Pharma's AR-105 flunks mid-stage study; shares down 27% premarket

  • Ultra-thinly traded micro cap Aridis Pharmaceuticals (NASDAQ:ARDS) slumps 27% premarket on light volume in reaction an unsuccessful Phase 2 clinical trial evaluating candidate AR-105, a fully human IgG1 monoclonal antibody, for the treatment of ventilator-associated pneumonia caused by Gram-negative Pseudomonas aeruginosa.
  • More news on: Aridis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,
  • Read more ...
Stock Information

Company Name: Aridis Pharmaceuticals Inc.
Stock Symbol: ARDS
Market: NASDAQ
Website: aridispharma.com

Menu

ARDS ARDS Quote ARDS Short ARDS News ARDS Articles ARDS Message Board
Get ARDS Alerts

News, Short Squeeze, Breakout and More Instantly...